Top

Published in:

11-12-2023 | Ropinirole | Review Article

Impulse control disorders in Parkinson’s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis

Authors: Lenise G. Soileau, Norris C. Talbot, Nicholas R. Storey, Noah J. Spillers, James V. D’antoni, Peter C. Carr, Connor M. Galardo, Patil Shilpadevi, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye

Published in: Neurological Sciences | Issue 4/2024

Abstract

Background

This analysis is the first systematic review and meta-analysis assessing occurrences of ICD in PD patients treated with oral DAs: ropinirole (ROP) and pramipexole (PRX). This study compares the two oral DAs to a transdermal patch, rotigotine (RTG).

Methods

We performed an extensive systematic search for eligible studies from PubMed, Embase, Cochrane Library, and Google Scholar. The data was analyzed by various software, including EndNote, Rayyan, PRISM, and RevMan. Two studies incorporating 658 patients collectively were assessed.

Results

This meta-analysis shows a significant correlation between the usage of PRX (25.3%) or ROP (21.8%) and the development of ICD in PD patients. Compared to the transdermal patch, RTG, PRX was found to have a significant relative risk (P < 0.0001) of 3.46 (95% CI 2.07–5.76), and ROP was found to have a significant relative risk (P < 0.0001) of 2.98 (95% CI 1.77–5.02). The data collected shows RTG is approximately three times less likely to cause ICDs than oral PRX and ROP.

Conclusion

The present investigation provides insight into ICD occurrences with PRX, ROP, and RTG to allow physicians to make more informed decisions on risk versus reward when deciding how to treat a PD patient with these drugs. However, related to various disclosed limitations, our conclusion cannot provide definitive practice protocols.

McHugh PC, Buckley DA (2015) The structure and function of the dopamine transporter and its role in CNS diseases. Vitam Horm 98:339–369CrossRefPubMed

Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2019) Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol 39(1):31–59CrossRefPubMed

Paus T (2001) Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nat Rev Neurosci 2(6):417–424CrossRefPubMed

Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8(3):218–226CrossRefPubMed

Depue RA, Collins PF (1999) Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci 22(3):491–517; discussion 518–569

Berridge KC, Kringelbach ML (2008) Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology 199(3):457–480CrossRefPubMedPubMedCentral

GBD 2016 Parkinson’s Disease Collaborators (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939–53

Focus On Parkinson’s Disease Research | National Institute of Neurological Disorders and Stroke [Internet]. [cited 2023 Oct 10]. Available from: https://www.ninds.nih.gov/current-research/focus-disorders/focus-parkinsons-disease-research

Sonne J, Reddy V, Beato MR (2023) Neuroanatomy, substantia nigra. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [cited 2023 Jul 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK536995/

10.

Sonne J, Goyal A, Lopez-Ojeda W (2023) Dopamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [cited 2023 Jul 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK535451/

11.

Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia AS, McNamara JO et al (2001) Circuits within the basal ganglia system. In: Neuroscience 2nd edition [Internet]. Sinauer Associates; [cited 2023 Jul 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10847/

12.

Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA (2012) Parkinson’s disease. Subcell Biochem 65:389–455CrossRefPubMedPubMedCentral

13.

Chaudhuri KR, Rizos A, Sethi KD (2013) Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm (Vienna) 120(9):1305–1320CrossRefPubMed

14.

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266. https://doi.org/10.1002/mds.27372. Erratum in: Mov Disord. 2018;33(12):1992

15.

Choi J, Horner KA (2022) Dopamine agonists [Internet]. StatPearls [Internet]. StatPearls Publishing; [cited 2023 Mar 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551686/

16.

Li C, Chen P, Smith MS (1999) Neuropeptide Y and tuberoinfundibular dopamine activities are altered during lactation: role of prolactin. Endocrinology 140(1):118–123CrossRefPubMed

17.

Inzelberg R, Schechtman E, Nisipeanu P (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson’s disease. Drugs Aging 20(11):847–855CrossRefPubMed

18.

Lewis MM, Van Scoy LJ, De Jesus S, Hakun JG, Eslinger PJ, Fernandez-Mendoza J et al (2023) Dopamine D1 agonists: first potential treatment for late-stage Parkinson’s disease. Biomolecules 13(5):829CrossRefPubMedPubMedCentral

19.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12(8):747–755. https://doi.org/10.1016/S1474-4422(13)70117-0CrossRefPubMedPubMedCentral

20.

Seeman P (2015) Parkinson’s disease treatment may cause impulse–control disorder via dopamine D3 receptors. Synapse 69(4):183–189MathSciNetCrossRefPubMed

21.

Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 30(2):121–127CrossRefPubMed

22.

Fariba KA, Gokarakonda SB (2023) Impulse control disorders. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [cited 2023 Oct 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562279/

23.

Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE (2009) Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 84(4):310–316CrossRefPubMedPubMedCentral

24.

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | PLOS Medicine [Internet]. [cited 2023 Oct 9]. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003583

25.

Li T, Zou S, Zhang Z, Liu M, Liang Z (2022) Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis. BMC Neurol 22(1):320CrossRefPubMedPubMedCentral

26.

Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRefPubMed

27.

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, HerranzBarcenas A, Vela L, Sanchez Alonso P et al (2014) Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85(8):840–844CrossRefPubMed

28.

Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B et al (2016) A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23(8):1255–1261CrossRefPubMed

29.

Hisahara S, Shimohama S (2011) Dopamine receptors and Parkinson’s disease. Int J Med Chem 2011:403039PubMedPubMedCentral

30.

Wood M, Dubois V, Scheller D, Gillard M (2015) Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol 172(4):1124–1135CrossRefPubMedPubMedCentral

31.

Seeman P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69(4):183–189MathSciNetCrossRefPubMed

32.

DeMaagd G, Philip A (2015) Part 2: introduction to the pharmacotherapy of Parkinson’s disease, with a focus on the use of dopaminergic agents. P T 40(9):590–600PubMedPubMedCentral

33.

Antonini A (2007) Continuous dopaminergic stimulation–from theory to clinical practice. Parkinsonism Relat Disord 13(Suppl):S24-28CrossRefPubMed

34.

Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34(4):966–978CrossRefPubMed

35.

Wolfschlag M, Håkansson A (2023) Drug-induced gambling disorder: epidemiology, neurobiology, and management. Pharmaceut Med 37(1):37–52PubMedPubMedCentral

36.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

37.

Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E et al (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41(1):19–75CrossRefPubMed

Title: Impulse control disorders in Parkinson’s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis
Authors: Lenise G. Soileau
Norris C. Talbot
Nicholas R. Storey
Noah J. Spillers
James V. D’antoni
Peter C. Carr
Connor M. Galardo
Patil Shilpadevi
Shahab Ahmadzadeh
Sahar Shekoohi
Alan D. Kaye
Publication date: 11-12-2023
Publisher: Springer International Publishing
Keywords: Ropinirole
Pramipexole
Rotigotine
Parkinson's Disease
Dopamine Agonist
Published in: Neurological Sciences / Issue 4/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07254-1

At a glance: The STEP trials

Springer Medicine

Impulse control disorders in Parkinson’s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2024

Impact of transcranial direct current stimulation combined with motor-cognitive intervention on post-stroke cognitive impairment

A video-atlas of levodopa-induced dyskinesia in Parkinson’s disease: terminology matters

Heterogenous electrophysiological features in early stage of hereditary transthyretin amyloidosis neuropathy

Intraluminal carotid thrombus leading to postpartum stroke: a case study

Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations

Primary peripheral nerve lymphoma: a case report and literature review